Drug Trial Radar · NCT07425899
A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Feb 26, 2026
Primary completion
Jun 5, 2026
Study completion Jun 5, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-722Drug
Oral
UpadacitinibDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration at steady state (Cmax,ss) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
- Time to maximum observed plasma concentration (Tmax) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
- Area under curve over the dosing interval at steady state (AUCtau,ss) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
- Observed plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of ABBV-722Time frame: Up to Day 6 in Period 2 and Up to Day 17 in Period 3
- Maximum observed plasma concentration at steady state (Cmax,ss) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
- Time to maximum observed plasma concentration (Tmax) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
- Area under curve over the dosing interval at steady state (AUCtau,ss) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
- Observed plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of UpadacitinibTime frame: Up to Day 7 in Period 1 and Up to Day 17 in Period 3
- Number of Participants with Adverse Events (AEs)Time frame: Approximately up to 91 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 279285
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.